These findings demonstrate that Danthron exerts potent antioxidant and anti-inflammatory effects through coordinated inhibition of EGFR-PI3K-AKT signaling and activation of the Nrf2-HO-1 axis, suggesting its promise as a multi-target therapeutic candidate for IBD. The gene discussed is AKT1; the disease is inflammatory bowel disease.